5 results about "Transplant recipient" patented technology

This invention relates to the field of medical technology, specifically to a method for preoperative risk assessment and prediction in liver transplant patients with hepatocellular carcinoma, comprising the following steps: Sample collection: selecting plasma samples and corresponding clinicopathological information from liver transplant recipients of hepatocellular carcinoma, and clarifying the inclusion and exclusion criteria for samples; Plasma cell-free DNA extraction and whole-genome sequencing: extracting and quality-controlling cell-free DNA from the plasma samples collected in step S1, constructing a sequencing library, and performing low-coverage whole-genome sequencing. This invention utilizes plasma-extracted cfDNA for whole-genome sequencing, combined with clinical testing information, to construct a preoperative risk assessment and prediction model for postoperative recurrence in liver transplant recipients of hepatocellular carcinoma based on non-invasive testing. This model can be used to predict the probability of recurrence-free survival before liver transplantation. The model derivation cohort integrates clinical records and circulating tumor DNA data for preoperative recurrence risk prediction.

The present invention relates to the use of mesenchymal stem cells to reduce inflammation and immune responses for neuromuscular injuries and limb transplants. A particular preferred embodiment relates to use of mesenchymal stem cells that are modified to express interleukin-10 in limb transplantation surgery. In particular embodiments, the present invention also provides a method of improving nerve and muscle regeneration and functional outcome for limb transplantation in a mammalian limb transplant recipient by administering to the limb transplant recipient a therapeutic amount of mesenchymal stem cells.

Disclosed herein are computer-implemented systems, kits, and methods for determining an amount of contributor-derived nucleic acids in a biological sample, from a transplant recipient, that comprises nucleic acids from two or more genetically distinct contributors. The determined amount of contributor-derived nucleic acids may be useful in monitoring the status of a transplant for, e.g., assessing a risk of transplant rejection. In some examples, the two or more genetically distinct contributors may comprise the transplant recipient, fetus, and transplant donor. In some examples, the two or more genetically distinct contributors may comprise the transplant recipient, first transplant donor, and second transplant donor. For example, the systems and methods determine an estimated percentage of the contributor-derived nucleic acids and / or estimated percentage of the fetal-derived nucleic acids.

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapies based on cytotoxic T cell (CTL)-recognized T cell epitopes (e.g., CMV epitopes), and can be used to prevent and / or treat CMV infection, reactivation, and / or disease (e.g., CMV-associated end-organ disease), especially in solid organ transplant recipients.